CareDx, Inc

Symbol: CDNA

NASDAQ

10.32

USD

Market price today

  • -3.1032

    P/E Ratio

  • 0.0000

    PEG Ratio

  • 534.35M

    MRK Cap

  • 0.00%

    DIV Yield

CareDx, Inc (CDNA) Stock Price & Analysis

Shares Outstanding

0M

Gross Profit Margin

0.63%

Operating Profit Margin

-0.37%

Net Profit Margin

-0.68%

Return on Assets

-0.39%

Return on Equity

-0.51%

Return on Capital Employed

-0.26%

Company general description and statistics

Sector: Healthcare
Industry: Diagnostics & Research
CEO:Mr. Abhishek Jain
Full-time employees:635
City:South San Francisco
Address:1 Tower Place
IPO:2014-07-17
CIK:0001217234

CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company also offers TruSight HLA, a next generation sequencing (NGS) based high resolution typing solution; Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.

General Outlook

When we look at how much money they make before expenses, they keep 0.634% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is -0.373%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of -0.679%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust -0.393% return, is a testament to CareDx, Inc's adeptness in optimizing resource deployment. CareDx, Inc's utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of -0.514%. Furthermore, the proficiency of CareDx, Inc in capital utilization is underscored by a remarkable -0.257% return on capital employed.

Stock Prices

CareDx, Inc's stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $9.96, while its low point bottomed out at $8.43. This variance in figures offers investors a lucid insight into the roller-coaster ride that is CareDx, Inc's stock market.

Liquidity Ratios

Analyzing CDNA liquidity ratios reveals its financial health of the firm. The current ratio of 401.83% gauges short-term asset coverage for liabilities. The quick ratio (366.94%) assesses immediate liquidity, while the cash ratio (105.28%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio401.83%
Quick Ratio366.94%
Cash Ratio105.28%

Profitability Ratios

CDNA profitability indicators offer a lens into its earnings landscape. A pretax profit margin of -67.83% underscores its earnings before tax deductions. The effective tax rate stands at -0.07%, revealing its tax efficiency. The net income per EBT, 100.07%, and the EBT per EBIT, 181.79%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of -37.31%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin-67.83%
Effective Tax Rate-0.07%
Net Income per EBT100.07%
EBT per EBIT181.79%
EBIT per Revenue-37.31%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 4.02, it details the span from stock purchase to revenue. The 4 days it takes to settle debts showcases its creditor relations. Meanwhile, a 1 cash conversion cycle and 549.00% receivables turnover rate reflect its cash flow efficiency and credit management, respectively.

cards.indicatorcards.value
Days of Sales Outstanding367
Days of Inventory Outstanding69
Operating Cycle135.73
Days of Payables Outstanding46
Cash Conversion Cycle90
Receivables Turnover5.49
Payables Turnover7.97
Inventory Turnover5.27
Fixed Asset Turnover4.30
Asset Turnover0.58

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, -0.34, and free cash flow per share, -0.52, depict cash generation on a per-share basis. The cash per share value, 4.41, showcases liquidity position. Lastly, the operating cash flow sales ratio, -0.07, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Operating Cash Flow per Share-0.34
Free Cash Flow per Share-0.52
Cash per Share4.41
Operating Cash Flow Sales Ratio-0.07
Free Cash Flow to Operating Cash Flow Ratio1.50
Cash Flow Coverage Ratio-0.54
Short Term Coverage Ratio-3.09
Capital Expenditure Coverage Ratio-1.99
Dividend Paid and Capex Coverage Ratio-1.99

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 7.06%, highlights its total liabilities relative to assets. With a debt-equity ratio of 0.13, we discern the balance between debt and equity financing. The long-term debt to capitalization, 9.76%, and total debt to capitalization, 11.58%, ratios shed light on its capital structure. An interest coverage of 231.92 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio7.06%
Debt Equity Ratio0.13
Long Term Debt to Capitalization9.76%
Total Debt to Capitalization11.58%
Interest Coverage231.92
Cash Flow to Debt Ratio-0.54
Company Equity Multiplier1.85

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 5.21, provides a glimpse into top-line earnings distributed across each share. Net income per share, -3.54, reflects the portion of profit attributed to each share. The book value per share, 4.86, represents the net asset value distributed per share, while the tangible book value per share, 3.26, excludes intangible assets.

cards.indicatorcards.value
Revenue Per Share5.21
Net Income Per Share-3.54
Book Value Per Share4.86
Tangible Book Value Per Share3.26
Shareholders Equity Per Share4.86
Interest Debt Per Share0.64
Capex Per Share-0.17

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, -12.89%, indicates top-line expansion, while the gross profit growth, -16.09%, reveals profitability trends. EBIT growth, -31.94%, and operating income growth, -31.94%, offer insights into operational profitability progression. The net income growth, -148.37%, showcases bottom-line expansion, and the EPS growth, -145.83%, measures the growth in earnings per share.

cards.indicatorcards.value
Revenue Growth-12.89%
Gross Profit Growth-16.09%
EBIT Growth-31.94%
Operating Income Growth-31.94%
Net Income Growth-148.37%
EPS Growth-145.83%
EPS Diluted Growth-145.83%
Weighted Average Shares Growth0.83%
Weighted Average Shares Diluted Growth0.83%
Operating Cash Flow Growth27.14%
Free Cash Flow Growth44.27%
10-Year Revenue Growth per Share73.95%
5-Year Revenue Growth per Share142.68%
3-Year Revenue Growth per Share26.10%
10-Year Operating CF Growth per Share-361.82%
5-Year Operating CF Growth per Share-204.19%
3-Year Operating CF Growth per Share-147.55%
10-Year Net Income Growth per Share-636.69%
5-Year Net Income Growth per Share-169.77%
3-Year Net Income Growth per Share-779.07%
10-Year Shareholders Equity Growth per Share123.78%
5-Year Shareholders Equity Growth per Share80.58%
3-Year Shareholders Equity Growth per Share-18.64%
Receivables Growth-23.00%
Inventory Growth1.24%
Asset Growth-10.75%
Book Value per Share Growth-39.85%
Debt Growth-12.25%
R&D Expense Growth-9.43%
SGA Expenses Growth-0.27%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 597,200,460, captures the company's total value, considering both debt and equity. Income quality, 0.10, assesses the reliability of reported earnings. The sales, general, and administrative to revenue ratio, 0.42, gauges operational efficiency, while the research and development to revenue, 29.20%, highlights investment in innovation. The ratio of intangibles to total assets, 17.75%, indicates the value of non-physical assets, and capex to operating cash flow, 50.25%, measures reinvestment capability.

cards.indicatorcards.value
Enterprise Value597,200,460
Income Quality0.10
Sales General and Administrative to Revenue0.42
Research and Development to Revenue29.20%
Intangibles to Total Assets17.75%
Capex to Operating Cash Flow50.25%
Capex to Revenue-3.30%
Capex to Depreciation-46.61%
Stock-Based Compensation to Revenue17.51%
Graham Number19.67
Return on Tangible Assets-47.74%
Graham Net Net1.12
Working Capital235,641,000
Tangible Asset Value175,291,000
Net Current Asset Value90,426,000
Average Receivables58,686,500
Average Payables11,407,000
Average Inventory19,351,500
Days Sales Outstanding66
Days Payables Outstanding45
Days of Inventory On Hand68
ROIC-34.50%
ROE-0.73%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 2.26, and the price to book ratio, 2.26, reflect the market's valuation relative to the company's book value. The price to sales ratio, 2.05, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, -20.82, and price to operating cash flows, -32.11, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio2.26
Price to Book Ratio2.26
Price to Sales Ratio2.05
Price Cash Flow Ratio-32.11
Enterprise Value Multiple-6.93
Price Fair Value2.26
Price to Operating Cash Flow Ratio-32.11
Price to Free Cash Flows Ratio-20.82
Price to Tangible Book Ratio2.47
Enterprise Value to Sales2.13
Enterprise Value Over EBITDA-7.28
EV to Operating Cash Flow-32.48
Earnings Yield-29.49%
Free Cash Flow Yield-4.28%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of CareDx, Inc (CDNA) on the NASDAQ in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is -3.103 in 2024.

What is the ticker symbol of CareDx, Inc stock?

The ticker symbol of CareDx, Inc stock is CDNA.

What is company IPO date?

IPO date of CareDx, Inc is 2014-07-17.

What is company current share price?

Current share price is 10.320 USD.

What is stock market cap today?

The market cap of stock today is 534354120.000.

What is PEG ratio in 2024?

The current 0.000 is 0.000 in 2024.

What is the number of employees in 2024?

In 2024 the company has 635.